At Roche, we focus our energy and investment in developing tests and treatments that change lives and give us more time with the people we love.
We are proud to be the UK’s leading provider of in vitro diagnostics tests and in 2022 more than 752 million1 Roche diagnostic tests were used by clinicians across the UK to confirm, rule out or manage health conditions including cancer, heart disease, diabetes, COVID-19, hepatitis, human papillomavirus (HPV) and many others. Designed by pathologists for pathologists, our lab-ready digital pathology solutions combine advanced diagnostic hardware and software to provide clinical insights with digital precision.
We work from bench to bedside – researching new medicines and diagnostics, running global clinical trials, and working in partnership with the NHS to ensure rapid uptake and delivery of our products and services.
Founded in 1896 in Basel, Switzerland, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
